Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer

2004 ◽  
Vol 44 (1) ◽  
pp. 74-82 ◽  
Author(s):  
Carsten Harms ◽  
Salama A. Salama ◽  
Carlos H. Sierra-Torres ◽  
Nohelia Cajas-Salazar ◽  
William W. Au
2019 ◽  
Vol 28 (6) ◽  
pp. 522-528 ◽  
Author(s):  
Varvara I. Minina ◽  
Marina L. Bakanova ◽  
Olga A. Soboleva ◽  
Anastasia V. Ryzhkova ◽  
Ruslan A. Titov ◽  
...  

Lung Cancer ◽  
2011 ◽  
Vol 73 (1) ◽  
pp. 25-31 ◽  
Author(s):  
Sukki Cho ◽  
Min Jung Kim ◽  
Yi Young Choi ◽  
Seung Soo Yoo ◽  
Won Kee Lee ◽  
...  

Author(s):  
Luz Stella Hoyos-Giraldo ◽  
Silvio Carvajal ◽  
Nohelia Cajas-Salazar ◽  
Martín Ruíz ◽  
Adalberto Sánchez-Gómez

2013 ◽  
Vol 40 (9) ◽  
pp. 5261-5273 ◽  
Author(s):  
L. Letkova ◽  
T. Matakova ◽  
L. Musak ◽  
M. Sarlinova ◽  
M. Krutakova ◽  
...  

2010 ◽  
Vol 28 (33) ◽  
pp. 4945-4952 ◽  
Author(s):  
Kouya Shiraishi ◽  
Takashi Kohno ◽  
Chiharu Tanai ◽  
Yasushi Goto ◽  
Aya Kuchiba ◽  
...  

Purpose To identify polymorphisms in DNA repair genes that affect responses to platinum-based doublet chemotherapy in patients with non–small-cell lung cancer (NSCLC). Patients and Methods In total, 640 patients with NSCLC who received platinum-based doublet chemotherapy in the National Cancer Center Hospital in Japan from 2000 to 2008 and whose responses were evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) participated in a study of the association between response and genotypes for 30 single nucleotide polymorphisms (SNPs) in 27 DNA repair genes. Candidate SNPs were selected in a discovery set of 201 patients, and their associations were validated in an independent set of 439 patients by prespecified P value criteria. Results Homozygotes for the minor allele TP53-72Pro of the Arg72Pro SNP in the TP53 gene showed a better response rate (54.3%) than those for the major allele TP53-72Arg (29.1%; P = 4.4 × 10−5) irrespective of therapeutic regimens, and minor allele homozygotes had significantly longer progression-free and overall survivals than major allele homozygotes (hazard ratio [HR], 0.85; 95% CI, 0.74 to 0.98; P = .020; and HR, 0.86; 95% CI, 0.74 to 0.99; P = .039). Minor allele carriers for SNP Lys940Arg in the poly (ADP-ribose) polymerase 1 (PARP1) gene showed a better response rate to the paclitaxel regimen (45.8%) than to the gemcitabine regimen (10.5%; P for interaction = .019). Conclusion Polymorphisms in the TP53 and PARP1 genes are involved in inter-individual differences in the response to platinum-based doublet chemotherapy in patients with NSCLC.


Author(s):  
M. Sarlinova ◽  
L. Majerova ◽  
T. Matakova ◽  
L. Musak ◽  
P. Slovakova ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document